Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have be...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1089066/full |
| _version_ | 1811177853138501632 |
|---|---|
| author | Desh Deepak Singh Hae-Jeung Lee Dharmendra Kumar Yadav |
| author_facet | Desh Deepak Singh Hae-Jeung Lee Dharmendra Kumar Yadav |
| author_sort | Desh Deepak Singh |
| collection | DOAJ |
| description | Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have been effectively used for patient treatment. High mortality rate is reported in HER2+ BC, due to availability of limited therapeutic options. Despite advances in systemic medications to treat metastatic breast cancer (MBC), HER2-positive MBC is still challenging for patients and treating clinicians. The clinical characteristics of the disease have changed after treatment with HER2-targeted therapy. Various types of Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with HER2+ BC including afatinib, lapatinib, neratinib, tucatinib, and pyrotinib, have been developed as HER2-targeted therapies. The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies. The emergence of drug resistance in anti-HER2 therapies has been observed. To overcome drug resistance and limited efficacy in current treatment options, nano formulations can be used in patients with HER2+ BC treatment. Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors. |
| first_indexed | 2024-04-11T06:08:16Z |
| format | Article |
| id | doaj.art-169673562bee467f896a2832b4e5bb03 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T06:08:16Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-169673562bee467f896a2832b4e5bb032022-12-22T04:41:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-12-011310.3389/fphar.2022.10890661089066Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancerDesh Deepak Singh0Hae-Jeung Lee1Dharmendra Kumar Yadav2Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, IndiaDepartment of Food and Nutrition, College of Bionano Technology, Gachon University, Seongnam-si, Gyeonggi-do, South KoreaDepartment of Pharmacy, Gachon Institute of Pharmaceutical Science, College of Pharmacy, Gachon University, Incheon, South KoreaBreast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have been effectively used for patient treatment. High mortality rate is reported in HER2+ BC, due to availability of limited therapeutic options. Despite advances in systemic medications to treat metastatic breast cancer (MBC), HER2-positive MBC is still challenging for patients and treating clinicians. The clinical characteristics of the disease have changed after treatment with HER2-targeted therapy. Various types of Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with HER2+ BC including afatinib, lapatinib, neratinib, tucatinib, and pyrotinib, have been developed as HER2-targeted therapies. The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies. The emergence of drug resistance in anti-HER2 therapies has been observed. To overcome drug resistance and limited efficacy in current treatment options, nano formulations can be used in patients with HER2+ BC treatment. Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors.https://www.frontiersin.org/articles/10.3389/fphar.2022.1089066/fullbreast cancerHER2-positivetyrosine kinase inhibitorsnovel combinationsclinical practice |
| spellingShingle | Desh Deepak Singh Hae-Jeung Lee Dharmendra Kumar Yadav Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer Frontiers in Pharmacology breast cancer HER2-positive tyrosine kinase inhibitors novel combinations clinical practice |
| title | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer |
| title_full | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer |
| title_fullStr | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer |
| title_full_unstemmed | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer |
| title_short | Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer |
| title_sort | clinical updates on tyrosine kinase inhibitors in her2 positive breast cancer |
| topic | breast cancer HER2-positive tyrosine kinase inhibitors novel combinations clinical practice |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1089066/full |
| work_keys_str_mv | AT deshdeepaksingh clinicalupdatesontyrosinekinaseinhibitorsinher2positivebreastcancer AT haejeunglee clinicalupdatesontyrosinekinaseinhibitorsinher2positivebreastcancer AT dharmendrakumaryadav clinicalupdatesontyrosinekinaseinhibitorsinher2positivebreastcancer |